MOBI Stock Forecast: Mobia Medical, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Mobia Medical, Inc. hold a median 12-month price target of $18 — +54.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
MOBI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Mobia Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (58): Smaller than most of the companies we track.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Mobia Medical, Inc. — and when they’d sell — is the membership.
MOBI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MOBI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +54.2% from it.
Of the 8 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 June 2026 | B of A Securities | Initiates | Buy | $16 |
| 2 June 2026 | BTIG | Initiates | Buy | $19 |
| 2 June 2026 | Goldman Sachs | Initiates | Buy | $31 |
| 2 June 2026 | JP Morgan | Initiates | Overweight | $15 |
| 26 Feb 2015 | Rosenblatt | Initiates | Buy | $10 |
| 4 Feb 2013 | Piper Sandler | Maintains | Overweight | $2.94 → $2.70 |
| 12 Nov 2012 | Piper Sandler | Maintains | Overweight | $3.20 → $2.94 |
| 14 Aug 2012 | Piper Sandler | Maintains | Overweight | $7.00 → $3.20 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MOBI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Mobia Medical, Inc. (MOBI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −560.5×
- Price / sales
- 9.7×
- Price / book
- −2.2×
- EV / EBITDA
- −10.3×
Cheaper than 99% of US stocks
Cheaper than 15% of US stocks
Cheaper than 95% of US stocks
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- 113.3%
- Earnings growth (YoY)
- —
- Gross margin
- 82.3%
- Operating margin
- −140.3%
- Net margin
- −139.3%
Higher than 94% of US stocks
Higher than 92% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
- Return on equity
- 30.8%
- Return on assets
- −96.6%
- Dividend yield
- —
Higher than 88% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MOBI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MOBI appears on the weeks it earns a place.
Frequently asked questions about MOBI stock
What is the MOBI stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Mobia Medical, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MOBI stock a buy right now?
Of the 4 analysts covering Mobia Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mobia Medical, Inc. 0 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MOBI?
As at 1 Aug 2026, Mobia Medical, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (58 of 100).
Will MOBI stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +54.2% from the last close, and Ticker Nerd's factor model ranks Mobia Medical, Inc. 0 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MOBI stock forecast for 2030?
No analyst covering Mobia Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MOBI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $19 over the next 12 months.
What does Mobia Medical, Inc. do?
Mobia Medical, Inc. is a commercial-stage medical device company focused on redefining stroke recovery for survivors with moderate to severe upper extremity motor impairments.
About Mobia Medical, Inc.
Mobia Medical, Inc. is a commercial-stage medical device company focused on redefining stroke recovery for survivors with moderate to severe upper extremity motor impairments. Its flagship product, the Vivistim Paired VNS System, is the first and only FDA-approved implantable solution that pairs targeted vagus nerve stimulation with functional movement exercises to promote neuroplasticity and enhance upper limb function in chronic ischemic stroke patients. This innovative therapy addresses a critical gap in post-stroke rehabilitation by driving meaningful, lasting improvements in motor recovery. Mobia Medical, Inc. supports patients, healthcare providers, and care partners through its commercial operations, emphasizing accessible stroke care solutions. The company operates within the neurostimulation and rehabilitation medical device sector, targeting the needs of chronic stroke survivors. Founded in 2007 and headquartered in Austin, Texas, Mobia Medical, Inc. plays a pivotal role in advancing therapeutic options for neurological recovery in the medical technology market.
CEO Mr. Richard John Foust · 167 employees · United States · https://www.mobia.com